|Product name||VEGF Rabbit Polyclonal Antibody|
|Immunogen||Recombinant Protein of VEGF of VEGFA|
|Reactivity||Human, Mouse, Rat|
|Applications notes||Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: IHC-P (1:100-1:200).|
|Preparation method||The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen|
|Storage buffer||PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.|
|Storage instructions||Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.|
|Shipping||Gel pack with blue ice.|
|Precautions||The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.|
|Background||VEGFA (vascular endothelial growth factor A) is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of VEGFA in mice resulted in abnormal embryonic blood vessel formation. VEGFA is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of VEGFA have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.|
|Others||VEGF protein detects endogenous levels of VEGFA.|
Fig.1. Immunohistochemical analysis of paraffin-embedded Human Liver Carcinoma Tissue using VEGF Rabbit pAb diluted at 1:500.
Fig.2. Immunohistochemical analysis of paraffin-embedded Human Kidney Tissue using VEGF Rabbit pAb diluted at 1:500.
Fig.3. Immunohistochemical analysis of paraffin-embedded Human Stomach Carcinoma Tissue using VEGF Rabbit pAb diluted at 1:500.
Author：Yuan-Feng Zeng, Yi-Sheng Xiao, et al Publication name：World Journal of Gastroenterology IF：3.43
1.The species of antibody reactivity should be the sample species that can be matched normally after Abbkine R&D experts have passed strict scientific verification. If your sample is not within the range of reactivity, in order to improve the efficiency and results of your experiment, it is not suggested to try other species. Otherwise, it may lead to sample mismatch and affect the effect of your experiment.
2.Please aliquot the antibody received as soon as possible and store it at -20℃, avoid repeated freezing and thawing, and use it within one year.
Welcome any form of communications, and better service will be provided here.
Address： Bldg C17, Optics Valley International Biomedicine Park, Wuhan, China. 430223